Abstract | BACKGROUND: METHODS AND RESULTS: To test this hypothesis, we examined whether endogenous or exogenous natriuretic peptides reduce the expression of CYP11B2 mRNA using real-time reverse transcription-polymerase chain reaction. By using HS 142-1, a functional guanylyl cyclase-A type receptor antagonist, we showed that angiotensin II (AngII) pretreated with HS 142-1 increased CYP11B2 mRNA expression (1.62+/-0.12-fold, HS 142-1+AngII 10(-7) mol/L versus AngII 10(-7) mol/L alone, P<0.0001). The treatment with exogenous (10(-6) mol/L) ANP and BNP reduced CYP11B2 mRNA expression ( ANP, P=0.0042; BNP, P=0.0012). CONCLUSIONS:
|
Authors | Teruhiko Ito, Michihiro Yoshimura, Shota Nakamura, Masafumi Nakayama, Yukio Shimasaki, Eisaku Harada, Yuji Mizuno, Megumi Yamamuro, Masaki Harada, Yoshihiko Saito, Kazuwa Nakao, Hiroki Kurihara, Hirofumi Yasue, Hisao Ogawa |
Journal | Circulation
(Circulation)
Vol. 107
Issue 6
Pg. 807-10
(Feb 18 2003)
ISSN: 1524-4539 [Electronic] United States |
PMID | 12591748
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- HS 142-1
- Polysaccharides
- RNA, Messenger
- Angiotensin II
- Natriuretic Peptide, Brain
- Atrial Natriuretic Factor
- Cytochrome P-450 CYP11B2
- Cyclic GMP
|
Topics |
- Angiotensin II
(pharmacology)
- Animals
- Animals, Newborn
- Atrial Natriuretic Factor
(pharmacology)
- Cells, Cultured
- Coculture Techniques
- Cyclic GMP
(metabolism)
- Cytochrome P-450 CYP11B2
(genetics, metabolism)
- Gene Expression
(drug effects)
- Myocytes, Cardiac
(cytology, drug effects, metabolism)
- Natriuretic Peptide, Brain
(pharmacology)
- Polysaccharides
(pharmacology)
- RNA, Messenger
(metabolism)
- Rats
- Reverse Transcriptase Polymerase Chain Reaction
|